특허번호

분류

대표 청구항

US11,084,865

제형

1. A vial comprising an ophthalmic formulation suitable for intravitreal administration that comprises: a vascular endothelial growth factor (VEGF) antagonist, an organic co-solvent, a buffer, and a stabilizing agent,

wherein said VEGF antagonist fusion protein is glycosylated and comprises amino acids 27-457 of SEQ ID NO:4; and

wherein at least 98% of the VEGF antagonist is present in native conformation following storage at 5° C for two months as measured by size exclusion chromatography.

US10,888,601

투여요법

1. A method for treating age related macular degeneration in a patient in need thereof, comprising intravitreally administering, to said patient, an effective amount of aflibercept which is 2 mg approximately every 4 weeks for the first 3 months, followed by 2 mg approximately once every 8 weeks or once every 2 months.

US11,053,280

정제방법

1. A method of producing aflibercept, comprising:

(a) producing a clarified harvest of cells cultured in a chemically defined medium (CDM); (b) binding aflibercept from said clarified harvest to a Protein A resin, wherein said aflibercept includes variants that have at least one oxidized amino acid residue selected from the group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof; (c) eluting said aflibercept of step (b) forming an affinity eluate, wherein said eluate has a first color; (d) subjecting said eluate comprising aflibercept to an anion exchange chromatography (AEX) column; and (e) collecting a flowthrough fraction, wherein said flowthrough fraction has a second color, and wherein said first color of said affinity eluate is a more intense yellow brown color than said second color of said flowthrough fraction when said affinity eluate and flowthrough fraction protein concentrations are normalized.

US11,104,715

배지

1. A method of producing aflibercept harvested from a host cell cultured in a chemically defined medium (CDM), comprising:

(a) providing a host cell genetically engineered to express aflibercept;

(b) culturing said host cell in said CDM under conditions suitable in which said host cell expresses said aflibercept wherein the cumulative concentration of nickel in said CDM is less than or equal to 0.4 μM or about 0.4 μM and one or more of the following: (중략)

; and (c) harvesting aflibercept produced by said host cell.